1/16
01:55 pm
incy
Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]
Low
Report
Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]
1/16
08:26 am
incy
Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
Low
Report
Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]
1/15
11:56 am
incy
Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]
Low
Report
Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]
1/14
08:31 pm
incy
Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]
Low
Report
Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]
1/14
04:41 pm
incy
Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]
Low
Report
Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]
1/13
05:50 pm
incy
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC]
Low
Report
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity [CNBC]
1/13
02:27 pm
incy
Incyte (NASDAQ:INCY) had its price target raised by analysts at TD Cowen from $101.00 to $128.00. They now have a "buy" rating on the stock.
Low
Report
Incyte (NASDAQ:INCY) had its price target raised by analysts at TD Cowen from $101.00 to $128.00. They now have a "buy" rating on the stock.
1/13
09:09 am
incy
Incyte (NASDAQ:INCY) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Incyte (NASDAQ:INCY) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/12
01:51 pm
incy
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]
Low
Report
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]
1/8
08:06 am
incy
Incyte (NASDAQ:INCY) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Incyte (NASDAQ:INCY) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/6
02:26 pm
incy
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins [Seeking Alpha]
Low
Report
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins [Seeking Alpha]
1/6
11:41 am
incy
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma [Yahoo! Finance]
Low
Report
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma [Yahoo! Finance]
1/6
10:37 am
incy
Incyte (NASDAQ:INCY) had its price target raised by analysts at Morgan Stanley from $92.00 to $94.00. They now have an "equal weight" rating on the stock.
Low
Report
Incyte (NASDAQ:INCY) had its price target raised by analysts at Morgan Stanley from $92.00 to $94.00. They now have an "equal weight" rating on the stock.
1/5
07:01 pm
incy
Incyte (NASDAQ:INCY) was given a new $119.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Incyte (NASDAQ:INCY) was given a new $119.00 price target on by analysts at Stifel Nicolaus.
1/5
07:37 am
incy
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma [Yahoo! Finance]
Low
Report
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma [Yahoo! Finance]
1/5
07:30 am
incy
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Low
Report
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
12/24
09:02 am
incy
Incyte (NASDAQ:INCY) was given a new $103.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Incyte (NASDAQ:INCY) was given a new $103.00 price target on by analysts at Truist Financial Corporation.
12/23
07:51 pm
incy
?????·???????·?????????????????????????????????????????????????? [CNET News]
Low
Report
?????·???????·?????????????????????????????????????????????????? [CNET News]
12/23
09:37 am
incy
Is It Too Late To Consider Incyte After A 45% Rally In 2025? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Incyte After A 45% Rally In 2025? [Yahoo! Finance]
12/22
10:37 pm
incy
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]
Low
Report
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]
12/22
02:56 am
incy
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance]
Low
Report
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance]
12/22
02:44 am
incy
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Low
Report
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
12/22
02:42 am
incy
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Low
Report
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
12/18
05:31 pm
incy
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]
Medium
Report
Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]
12/18
08:00 am
incy
Incyte to Present at Upcoming Investor Conference
Low
Report
Incyte to Present at Upcoming Investor Conference